EyePoint Pharmaceuticals (EYPT) just shared that its pivotal Phase 3 trial for DURAVYU in wet age-related macular degeneration has passed the second independent safety committee review. This marks a ...

Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.

In a first-in-human phase 1/2a clinical trial, researchers used adult stem cells to help restore vision in people with age-related macular degeneration. In the United States, age-related macular degen ...

Millions of Americans are or will experience some form of macular degeneration, which reduces central vision. This can make ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

A wireless retinal implant called PRIMA is changing that reality by helping blind patients read and recognize faces again.

Coave Therapeutics SA has nominated a lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

I’m certain the family has heard her version of the truth that most likely has little resemblance to the actual facts. How do I handle this situation?